Kini SD, et al. - Researchers evaluated the data concerning the use of bevacizumab for the treatment of epistaxis in subjects with hereditary hemorrhagic telangiectasias (HHT) and provided the guidance related to its use. They suggested the need for new therapeutic options as the treatment was largely ineffective or invasive with significant probable dilemmas. But they found it useful in overcoming the frequency, duration, and severity of epistaxis among HHT cases.